Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS_SW01 Cells Injection for Primary Ovarian Insufficiency
NCT07551895Phase 2Not yet recruiting
- Sponsor
- Huishan Biotech
- Start
- Apr 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, randomised, double-blind trial in primary ovarian insufficiency (POI) (4 arms), sponsored by Huishan Biotech. Primary endpoint: Dose-Limiting Toxicity at 28 days. Planned start Apr 2026; status: not yet recruiting.
02
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT07551895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551895.